Welcome to our dedicated page for Aclarion Warrant news (Ticker: ACONW), a resource for investors and traders seeking the latest updates and insights on Aclarion Warrant stock.
Aclarion, Inc. (Nasdaq: ACON, ACONW) is a pioneering healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The company's flagship product, Nociscan, is a revolutionary SaaS platform designed to noninvasively help physicians distinguish between painful and nonpainful discs in the spine, providing essential insights into the location of chronic low back pain. This innovative solution transforms complex MRS data into clear, actionable reports for medical professionals, enhancing patient diagnosis and treatment strategies.
Aclarion's business model is centered around delivering Nociscan reports to medical professionals, with all revenues generated from contracts with customers in the United States. Notably, Aclarion has seen a significant acceleration in the pace of Nociscan orders, with the last 250 scans being completed 2.5 times faster than the first 250. The company anticipates further growth as additional MRI scanners, including those from Siemens and Philips, are activated for key opinion leader surgeons.
Recent achievements include the completion of 1,000 commercial Nociscan exams, with 36% of these studies conducted in the past year alone. This milestone underscores the growing adoption of Aclarion's strategy and its journey towards becoming the standard of care in the industry. The company's patent portfolio is robust, featuring 22 U.S. patents, 17 international patents, and several pending applications, including exclusive licenses from Regents of the University of California.
Aclarion has also initiated strategic partnerships, such as the agreement with Alphatec Spine, Inc., to integrate Nociscan within ATEC’s AlphaInformatiX platform. This partnership aims to enhance clinical outcomes and reduce procedural costs by providing surgeons with comprehensive data on one platform.
Financially, Aclarion has strengthened its position through several financing transactions, reducing debt and increasing available cash. These funds will support key initiatives, including the CLARITY trial, which aims to validate the superior surgical outcomes associated with Nociscan.
With a commitment to advancing the field of augmented intelligence and MR spectroscopy, Aclarion continues to lead the way in addressing the global healthcare problem of chronic low back pain, impacting millions worldwide.
Aclarion (NASDAQ: ACON) announced that its Nociscan product is featured in the RSNA Edition of Siemens Healthineers magazine, MAGNETOM Flash. The article showcases how physicians incorporate Nociscan into their clinical practices for chronic low back pain patients. Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain. The feature will be highlighted at the RSNA annual meeting from December 1-4, 2024, and is expected to serve as a valuable reference for the medical community.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the upcoming Virtual Investor Summit Microcap Event on November 21st, 2024. The company will deliver a presentation from 3:30 PM to 4:00 PM ET and will be available for one-on-one meetings throughout the day.
The event will showcase 40 micro-cap companies with catalysts and strong market performance. The presentation will be accessible via webcast, and qualified investors can register for complimentary access to participate in live Q&A sessions.
Aclarion (Nasdaq: ACON, ACONW), a healthcare technology company specializing in chronic low back pain location identification through biomarkers and AI algorithms, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , is scheduled for October 15, 2024.
CEO Brent Ness will represent Aclarion in a fireside chat at 2:00 PM ET. The summit will feature presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology.
Maxim senior analysts will host these sessions, providing insights into the participating companies. Interested parties can reserve their seats for the virtual event through a provided link.
Aclarion, Inc. (Nasdaq: ACON) announced that its Nociscan AI solution played a key role in a study to better understand Modic changes (MC) in chronic low back pain (cLBP) patients. The study, presented at the 50th International Society for the Study of the Lumbar Spine Annual Meeting 2024, utilized Nociscan to measure intradiscal propionic acid (PA) levels adjacent to vertebral endplates with MC.
The research, conducted by the REACH Center at UCSF, aimed to clarify the biopsychosocial mechanisms of cLBP. Results suggest that PA levels may be useful in understanding why some MC patients improve or respond to treatment while others do not. Nociscan's ability to noninvasively quantify chemical biomarkers associated with disc pain could potentially lead to personalized treatment plans for cLBP patients, including the possibility of using antibiotics as a first-line treatment for those with high PA levels.
Aclarion, Inc. (Nasdaq: ACON) has provided a corporate update on their Nociscan AI technology, which aids in identifying chronic low back pain sources. Key milestones include:
1. Three of four largest private UK insurers now cover Nociscan
2. Partnership with ten prominent KOL surgeons in the US
3. Strategic partnership with ATEC to expand KOL network
4. Multiple commercial agreements in key US markets
5. Participation in NIH's BEST Trial with 800+ patients
6. Launch of CLARITY, a flagship clinical study
The company's technology is protected by 23 US patents and 17 international patents. Aclarion aims to establish Nociscan as a standard of care for chronic low back pain, addressing a $134 billion annual healthcare expenditure in the US.
Aclarion (NASDAQ: ACON) has announced the completion of the first Nociscan exams for patients enrolled in the LIFEHAB Trial in Norway. This randomized controlled trial is comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for 202 patients with chronic low back pain. Nociscan, Aclarion's technology, uses magnetic resonance spectroscopy (MRS) biomarkers to help identify patient improvement following treatment.
The trial began enrolling patients in Q2 2024, with six patients completing Nociscan exams by late August. Aclarion's CEO, Brent Ness, expressed excitement about the trial's progress and Nociscan's potential role in determining optimal treatment options. The company is also involved in other research studies, including trials in Rome and two NIH studies, as it aims to establish Nociscan as the gold standard for disc treatment decisions in low back pain research.
Aclarion, Inc. (Nasdaq: ACON) has launched a program to develop a statewide network of providers in New Jersey utilizing Nociscan for personal injury and workers compensation cases. Led by Dr. Justin Kubeck of Ocean Pain and Spine, the initiative aims to improve objective evaluation of chronic low back pain patients in these complex legal scenarios. Nociscan's AI technology measures biomarkers in lumbar discs correlated to pain and structural integrity, providing objective data for treatment recommendations and legal defenses.
The average settlement for personal injury claims involving neck and back in New Jersey is $918,967, while work-related accidents causing such injuries have a national average settlement of $148,750. Aclarion plans to expand this model to other U.S. markets, targeting a population well-suited for advanced biomarker identification through the Nociscan platform.
Aclarion, Inc. (Nasdaq: ACON) has expanded its Clinical Utility and Economic (CLUE) Trial to New Jersey, with Dr. Justin Kubeck of Ocean Pain and Spine joining the study. The CLUE trial aims to demonstrate how Nociscan's AI-generated data impacts treatment decisions for chronic low back pain. Nociscan is Aclarion's SaaS platform that noninvasively helps physicians identify painful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain.
Dr. Kubeck is the second surgeon to join CLUE, following Dr. John Keller in Michigan. Aclarion expects more spine surgeons to participate, rapidly providing data to payers on Nociscan's impact on treatment planning. The company aims to address the global issue of degenerative spine disease and low back pain, which affects 266 million people worldwide.
Aclarion (NASDAQ: ACON) has launched the Clinical Utility and Economic (CLUE) Trial to quantify how often Nociscan's AI-generated biomarker data changes surgical treatment plans for chronic low back pain. The multi-center study aims to provide insights into the real-world value of Nociscan as a decision support tool. Surgeons will determine their treatment plan before and after receiving Nociscan data, allowing Aclarion to assess the tool's influence on surgical decisions.
The CLUE trial complements the ongoing CLARITY study, which focuses on demonstrating improved surgical outcomes with Nociscan. CLUE's format is inspired by HeartFlow's evidence strategy, which led to changes in coronary artery disease assessment. Aclarion expects multiple physicians and sites to enroll in CLUE in the coming months, adding practical data to their expanding clinical evidence base.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis, has announced its participation in the upcoming Virtual Investor Summit on August 20th, 2024. The company, which utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in locating chronic low back pain sources, will be presenting at 4:00 PM ET.
Investors interested in attending the presentation can access it via the provided webcast link. Additionally, there's an opportunity for one-on-one meetings with Aclarion's management team, which can be arranged through the Investor Summit Group's registration process.
FAQ
What is the current stock price of Aclarion Warrant (ACONW)?
What does Aclarion, Inc. do?
What is Nociscan?
How does Aclarion generate revenue?
What recent achievements has Aclarion made?
What strategic partnerships has Aclarion formed?
What is the CLARITY trial?
How does Nociscan work?
What is Aclarion's market focus?
What financial steps has Aclarion taken recently?
How does Aclarion's technology benefit physicians?
